Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Stem Cell Therapeutics Corp.    R5W   CA8585721001

STEM CELL THERAPEUTICS CORP. (R5W)
Mes dernières consult.
Most popular
  Report  
SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Stem Cell Therapeutics Corp. : Stem Cell Therapeutics Completes Trillium Merger and Issues Stock Options

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/10/2013 | 03:45am CEST

FOR IMMEDIATE RELEASE TSX-Venture Exchange: SSS

STEM CELL THERAPEUTICS COMPLETES TRILLIUM MERGER AND ISSUES STOCK OPTIONS

Toronto, Canada, April 9, 2013 - Stem Cell Therapeutics Corp. (TSX-V:SSS) ("SCT"), a life sciences company developing stem cell-related technologies, today announced that it has completed its merger with Trillium Therapeutics Inc. ("Trillium") previously announced on February 4, 2013. The shareholders of Trillium voted overwhelmingly to support the merger.

The company also announced the issuance of 2,560,197 stock options under its stock option plan to directors, officers and employees reflecting the addition of the executives and staff of the merged entity. The options have an exercise price of $0.25 and a term of ten years. The issuance of stock options is subject to acceptance by the TSX Venture exchange.

About Stem Cell Therapeutics:

Stem Cell Therapeutics Corp. (TSX-V: SSS) develops stem cell-based therapeutics through partnerships with research institutions and technology transfer organizations. SCT's objectives include the sourcing and acquisition of stem cell-related development opportunities, and securing capital for the advancement of its licensed or acquired products. The Corporation's intended corporate acquisitions and licensed acquisitions are positioning it principally in the field of cancer stem cell therapeutic development. SCT is a member of the Centre for Commercialization of Regenerative Medicine consortium. For more information, visit: www.stemcellthera.com

Forward Looking Statements

This press release may contain forward-looking statements, which reflect SCT's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the satisfaction of the conditions precedent to the exercise of the option to acquire a license to certain technologies owned by University Health Network; the exercise of the option to acquire a license to
certain technologies owned by University Health Network; the execution and delivery of a definitive license agreement with University Health Network if SCT determines to exercise the University Health Network option; changing market conditions; the successful and timely completion of pre-clinical and clinical studies; the establishment of corporate alliances; the impact of competitive products and pricing; new product development risks; uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in SCT's ongoing quarterly and annual reporting, including in the base shelf prospectus dated March 1, 2011 and any prospectus supplement. Except as required by applicable securities laws, SCT undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT: Niclas Stiernholm

Chief Executive Officer

Stem Cell Therapeutics Corp. [email protected]

+1 416 595 0627 www.stemcellthera.com

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on STEM CELL THERAPEUTICS COR
04/18Trillium Therapeutics Reports TTI-622 Preclinical Data at the 2018 AACR Annua..
GL
04/16TRILLIUM THERAPEUTICS : AACR 2018 Abstract 2709
PU
04/16TRILLIUM THERAPEUTICS : AACR 2018 Abstract 2720
PU
04/10TRILLIUM THERAPEUTICS : Provides Update on its TTI-621 and TTI-622 Clinical Prog..
PU
04/10Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 Clinical Pr..
GL
03/20Trillium Therapeutics’ TTI-621 Receives Orphan Drug Designation for the..
GL
02/09TRILLIUM THERAPEUTICS : to Present at Investor and Scientific Conferences in the..
MW
01/19TRILLIUM THERAPEUTICS INC : Blog Exposure - Trillium Announces Changes to Senior..
AC
01/17TRILLIUM THERAPEUTICS : Enhances Senior Management Team to Support Further Clini..
MW
2017TRILLIUM THERAPEUTICS : ASH 2017 Abstract 4076
PU
More news
Financials ( CAD)
Sales 2018 -
EBIT 2018 -51,0 M
Net income 2018 -49,9 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 0
Capi. / Sales 2019 0
Capitalization 112 M
Chart STEM CELL THERAPEUTICS COR
Duration : Period :
Stem Cell Therapeutics Cor Technical Analysis Chart | R5W | CA8585721001 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 14,0  CAD
Spread / Average Target 72%
EPS Revisions
Managers
NameTitle
Niclas Stiernholm President, Chief Executive Officer & Director
Calvin R. Stiller Chairman
James T. Parsons Chief Financial Officer
Robert A. Uger Chief Scientific Officer
Henry Friesen Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
STEM CELL THERAPEUTICS CORP.87
GILEAD SCIENCES1.51%94 816
VERTEX PHARMACEUTICALS3.88%39 523
REGENERON PHARMACEUTICALS-17.01%33 601
GENMAB18.71%12 384
BEIGENE LTD (ADR)69.87%9 095